Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®
Brief Summary: Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.


Options:
A: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
B: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
C: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks
D: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A